摘要目的 探讨MRI检查在英夫利昔单克隆抗体(IFX)联合挂线治疗克罗恩病肛瘘疗效评估中的应用价值,并分析深度愈合的影响因素.方法 采用回顾性病例对照研究.收集2010年8月至2016年10月南京中医药大学附属医院收治的57例行IFX联合挂线治疗克罗恩病肛瘘患者的临床资料;男39例,女18例;年龄为(24±9)岁,年龄范围为14～58岁.57例患者术前及术后均行MRI检查.观察指标:(1)随访情况.(2)克罗恩病肛瘘深度愈合的影响因素分析.采用门诊或住院复查方式进行随访,了解患者临床愈合情况.随访时间截至2017年10月.正态分布的计量资料以Mean SD表示,偏态分布的计量资料以M(范围)表示.计数资料以绝对数或百分比表示.单因素分析采用x2检验,将P＜0.15的因素纳入多因素分析,多因素分析采用Logistic回归模型.结果 (1)随访情况:57例行IFX联合挂线治疗克罗恩病肛瘘患者均获得随访,随访时间为(40±24)个月.57例患者随访期间,临床应答24例,临床长期愈合33例.24例临床应答患者中,术后MRI检查示均有T2加权成像(T2WI)瘘管高信号.33例临床长期愈合患者中,16例术后MRI检查示T2WI瘘管高信号消失,被纤维化组织替代,达到深度愈合;17例虽无临床症状,但术后MRI检查示T2WI仍存在瘘管高信号,未达到深度愈合.(2)克罗恩病肛瘘深度愈合的影响因素分析.单因素分析结果显示:瘘管范围是影响克罗恩病肛瘘深度愈合的相关因素(x2=4.312,P＜ 0.05).多因素分析结果显示:瘘管数目为单条且有分支,IFX维持治疗≤3次是克罗恩病肛瘘深度愈合的独立危险因素(比值比=4.377,4.296,95％可信区间为1.124～ 17.043,1.158～ 15.940,P＜0.05);瘘管范围位于肛提肌下方是克罗恩病肛瘘深度愈合的独立保护因素(比值比=0.182,95％可信区间为0.041～0.815,P＜0.05).结论 IFX联合挂线治疗克罗恩病肛瘘,临床长期愈合的患者并未全部达到深度愈合,需经MRI检查进一步评估其愈合情况.瘘管数目为单条且有分支,IFX维持治疗≤3次是克罗恩病肛瘘深度愈合的独立危险因素,瘘管范围位于肛提肌下方是克罗恩病肛瘘深度愈合的独立保护因素.

abstractsObjective To investigate the application value of magnetic resonance imaging (MRI) examination in the efficacy evaluation of infliximab combined with seton placement for perianal fistulizing Crohn's disease (PFCD) and influencing factors of deep remission.Methods The retrospective case-control study was conducted.The clinicopathological data of 57 patients with PFCD who were admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine from August 2010 to October 2017 were collected.There were 39 males and 18 females,aged (24±9)years,with a range of 14-58 years.Patients underwent MRI examination preoperatively and postoperatively.Observation indicators:(1) follow-up situations;(2) influencing factors analysis of deep remission of PFCD.Follow-up using outpatient and inpatient reexamination was performed to detect clinical recovery of patients up to October 2017.Measurement data with normal distribution were represented as Mean±SD.Measurement data with skewed distribution were described as M (range).Count data were represented as absolute number or percentage.The univariate analysis was performed using the chi-square test.The multivariate analysis was done using the logistic regression model,using P＜0.15 as an inclusion criteria in the univariate analysis.Results (1) Follow-up situations:57 patients with PFCD undergoing inflixmab combined with seton placement were followed up for (40±24)months.During the follow-up,24 of 57 patients had clinical response,33 had long-term clinical healing.The fistulas of 24 patients with clinical response presented as high signal on T2 weighted image (T2WI) of postoperative MRI.Of 33 patients with long-term clinical healing,the fistulas of 16 patients with deep remission presented loss of high signal and replacement of fibrosis tissue on T2WI of postoperative MRI,the fistulas of 17 patients without deep remission presented as high signal on T2WI of postoperative MRI.(2) Influencing factors analysis of deep remission of PFCD:results of univariate analysis showed that extent of fistula was related factors affecting deep remission of PFCD (x2 =4.312,P＜0.05).Results of multivariate analysis showed that a single fistula complicated with branches and times of infliximab maintenance treatment ≤3 were independent risk factors affecting deep remission of PFCD (odds ratio=4.377,4.296,95％ confidence interval:1.124-17.043,1.158-15.940,P＜0.05) and fistula under levator ani muscle was an independent protective factor affecting deep remission of PFCD (odds ratio =0.182,95％ confidence interval:0.041-0.815,P＜ 0.05).Conclusions Partial patients with long-term clinical healing can achieve deep remission after Infliximab combined with seton placement for perianal fistulizing Crohn's disease,requiring MRI examination to further evaluate recovery situations.A single fistula complicated with branches and times of infliximab maintenance treatment ≤ 3 are independent risk factors affecting deep remission of PFCD and fistula under levator ani muscle is an independent protective factor affecting deep remission of PFCD.